Jami Rubin - Bloomberg

JAMI RUBIN

Related Articles

Teva Faces Israel Backlash on Jobs Amid Cost-Cut Plan
3 months ago

Pfizer Breakup Talk Stoked by Discount to Drug Stocks
3 months ago

Pfizer Will Consider Split of Drug Units, CEO Read Says
4 months ago

Bristol-Myers Tops Profit Estimates on Tax Benefit
4 months ago

Pfizer’s Possible Unit Shuffle Triggers Breakup Concern
4 months ago

Teva Focuses on Central Nervous System, Respiratory Drugs
5 months ago

Teva Focuses on Central Nervous System, Respiratory Drugs
5 months ago

Lilly Last Hope for Alzheimer’s as Pfizer, J&J Bow Out
10 months ago

Lilly Profit Beats Analyst Estimates as Cymbalta Sales Rise
10 months ago

Pfizer-J&J Alzheimer’s Drug Fails to Aid Cognition
10 months ago

U.S. Stocks Rise as S&P 500 Posts Best Start Since 1998
14 months ago

U.S. Stocks Fall After S&P 500 Rallies to Four-Year High
14 months ago

Pfizer Rises After Goldman Raises Potential for Full Breakup
14 months ago

Pfizer’s Lipitor Plan Might Not Be ‘Worth It,’ Watson CEO Says
16 months ago

Pfizer Needs to Rebuild After Lipitor
18 months ago

Abbott Spinoff May Fetch $54 Billion as Humira Tempts Rivals
19 months ago

J&J’s Prostate Drug Extends Life as Spur to $5 Billion Market
24 months ago

J&J Will Seek FDA Approval by 2013 for Alzheimer’s Drug
24 months ago

J&J AIDS Pill Signals $9 Billion in Sales to Ease Recall Woes
24 months ago

Buy Bristol-Myers Calls as Stock May Advance, Goldman Says
27 months ago

Show More News

TOOLS
Watchlist | Stock Finder | Saved